Flagship explainer

How AYTU BIOPHARMA, INC makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$57.6M · 100%Cost of revenue$20.8M · 36%Gross profit$36.8M · 64%Operating income−$8.3M · −14%Income before tax−$14.2M · −25%Income tax$21000 · 0%Net income−$14.3M · −25%As of 2026-06-30 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$57.6M100%
Cost of revenue$20.8M36%
$36.8M64%
−$8.3M−14%
Income before tax−$14.2M−25%
Income tax$210000%
−$14.3M−25%
Source: · event Jun 30, 2026 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full AYTU BIOPHARMA, INC analysis at Buy Like Buffett